The short answer
Chromium may add to glucose lowering with glyburide, but the size of the added hypoglycemia risk is not established. The concern supports reviewing use and glucose readings, not an automatic dose change.
What this answer covers
Oral trivalent chromium supplements; studied chromium picolinate differs from other salts and dietary intake.
- Supplement or preparation
- Chromium
- Medication ingredient
- glyburide
The precaution is broader than one drug
NIH’s chromium guidance warns of possible additive glucose lowering with diabetes medicines. Glyburide itself can cause serious lows, making this a reasonable conditional precaution.
The clinical trial used glipizide
A chromium-picolinate trial improved insulin sensitivity and glucose control during glipizide treatment. It did not use glyburide or establish a glyburide-specific hypoglycemia rate.
Glyburide already has a hypoglycemia risk
Glyburide stimulates insulin release and can cause serious low glucose. Poor intake, alcohol, kidney or liver impairment, and other glucose-lowering treatment can increase susceptibility. These risks do not provide a supplement-specific event rate.
Review changes without adjusting the prescription yourself
Tell the diabetes team when starting or stopping the supplement and follow the prescribed glucose-monitoring and low-glucose treatment plan. Do not change the glyburide dose or assume a short spacing gap prevents a glucose effect.
Evidence and practical considerations
Side effects & toxicity
NIH class-level precaution and exact glyburide hypoglycemia warning support conditional monitoring, not proven incidence; glipizide trial explicitly indirect.
- Exact scope
- Oral trivalent chromium supplements; studied chromium picolinate differs from other salts and dietary intake. with Oral glyburide RxCUI 4815 IN, synonym glibenclamide; distinct formulation dosing retained.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair-event rate or arbitrary timing interval.
Factors that may matter: Preparation; Dose; Kidney/liver function; Food intake; Other glucose-lowering treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral glyburide
Glyburide stimulates insulin release and can cause severe hypoglycemia. Renal/hepatic impairment, deficient intake, alcohol and multiple glucose-lowering medicines increase susceptibility. Meal and individualized dose instructions apply.
How this applies: Exact oral glyburide active ingredient and named formulation.
Not glipizide, glimepiride or gliclazide. Formulations have different strengths and prescribing instructions; no supplement-specific adverse-event rate.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral glyburide
Glyburide stimulates insulin release and can cause severe hypoglycemia. Renal/hepatic impairment, deficient intake, alcohol and multiple glucose-lowering medicines increase susceptibility. Meal and individualized dose instructions apply.
How this applies: Exact oral glyburide active ingredient and named formulation.
Not glipizide, glimepiride or gliclazide. Formulations have different strengths and prescribing instructions; no supplement-specific adverse-event rate.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact glyburide; original drug, preparation and endpoint retained.
Chromium picolinate with glipizide GITS, not glyburide; no clinical hypoglycemia rate supplied in the abstract.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
NIH ODS describes possible additive glucose lowering with diabetes medicines and inconsistent clinical benefit.
How this applies: Indirect for exact glyburide; original drug, preparation and endpoint retained.
General diabetes-medication precaution, not a quantified glyburide trial; trivalent supplements, not industrial hexavalent chromium.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glyburide article distinguishing direct drug warnings, comparator studies and indirect supplement evidence. | |
| Research summary published |
Article revision: fe1bca6328498e7e
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.